

Belief BioMed and Grand Life Sciences partner for Hemophilia A Gene therapy in China

March 23, 2026 | News

To accelerate access to innovative therapies and advance the gene therapy industry in China



Belief BioMed and Grand Life Sciences have signed an exclusive collaboration to commercialize BBM-H803 for hemophilia A treatment in Mainland China, Hong Kong, Macau, and Taiwan, aiming to accelerate access to innovative therapies and advance the gene therapy industry.

The agreement was signed between Xiao Xiao, Co-founder, Chairman and CSO of Belief BioMed, and Zenghui, Feng, Chairman of Grand Life Sciences. The collaboration underscores the shared commitment of both sides to leverage their respective strengths and resources in their respective fields, to accelerate the commercialization process of the product, help hemophilia A patients access innovative treatment option, and jointly promote the development of the gene therapy industry.

Dr. Xiao Xiao, Co-founder, Chairman and Chief Science Officer of Belief BioMed, said, "Belief BioMed focuses on the cutting-edge gene therapy field, with our product pipeline covering the rare and common diseases, striving to fill a large number of unmet clinical needs. In 2025, we successfully launched China's first gene therapy for Hemophilia B, BBM-H901, providing a novel treatment option for patients in this field. Now, turning to the treatment of hemophilia A, we are delighted to forge this strategic partnership with Grand Life Sciences. By combining Belief BioMed's solid clinical development expertise with Grand Life Sciences' robust commercialization capabilities, we are creating a powerful synergy to jointly advance the commercialization of gene therapies for hemophilia A. We look forward to bringing this new treatment option to hemophilia A patients in China."

Mr. Zenghui Feng, Chairman of Grand Life Sciences Group, said, "Leveraging our extensive blood product resources of its subsidiary, Grand Shuyang, and deep expertise in the field of hematology, this collaboration with Belief BioMed in hemophilia A represents a pivotal strategic move to build our innovative pipeline. We look forward to integrating Belief BioMed's cutting-edge R&D capabilities with Grand Life Sciences' mature commercialization platform and market channels. Together, we aim to efficiently accelerate the patient access to this innovative therapy in China. Our shared goal is to enable more hemophilia A patients to benefit earlier, relieving them from the physical burden of frequent injections and the fear of bleeding episodes."